Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 1/20 | 0.54 |
| ▸ | PRKCI | P41743 | 1/20 | 0.52 |
| ▸ | KIF11 | P52732 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.47 |
| ▸ | QDPR | P09417 | 1/20 | 0.43 |
| ▸ | CYP17A1 | P05093 | 5/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.42 |
| ▸ | CYP11B1 | P15538 | 4/20 | 0.42 |
| ▸ | CYP11B2 | P19099 | 4/20 | 0.42 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.42 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.40 |
| ▸ | CNR1 | P21554 | 1/20 | 0.39 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.39 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.38 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27775798 | 0.85 | HSD17B1 (0.43) | CYP3A4 | |
| SCHEMBL15411832 | 0.83 | NOTUM (0.68) | NOTUMPRKCIKIF11LMNAMAPT | |
| SCHEMBL12070468 | 0.80 | NOTUM (0.65) | NOTUMPRKCIKIF11LMNAMAPT | |
| SCHEMBL12452342 | 0.80 | NOTUM (0.65) | NOTUMPRKCIKIF11LMNAMAPT | |
| SCHEMBL14425853 | 0.80 | NOTUM (0.65) | NOTUMPRKCIKIF11LMNAMAPT | |
| SCHEMBL23729172 | 0.80 | NOTUM (0.65) | NOTUMPRKCIKIF11LMNAMAPT | |
| SCHEMBL95329 | 0.80 | ALDH1A1 (0.50) | NOTUMLMNAMAPTCYP3A4 | |
| SCHEMBL5786570 | 0.80 | NOTUM (0.81) | NOTUMPRKCIKIF11LMNAMAPT | |
| SCHEMBL3032949 | 0.78 | CYP2A6 (0.62) | LMNAMAPTPRMT6CYP17A1CYP3A4 | |
| SCHEMBL8383567 | 0.78 | NOTUM (0.79) | NOTUMPRKCIKIF11LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1663204-B1 | C-KIT MODULATORS AND METHODS OF USE | EXELIXIS INC (US) | 2014-05-07 | — | — | EP | claimed |
| US-20070099958-A1 | Protease inhibitors | PROZYMEX A/S (DK) | 2007-05-03 | — | — | US | claimed |
| EP-1638925-A1 | PROTEASE INHIBITORS | Prozymex A/S (DK) | 2006-03-29 | — | — | EP | claimed |
| WO-2004110988-A1 | PROTEASE INHIBITORS | PROZYMEX A/S (DK) | 2004-12-23 | — | — | WO | claimed |
| WO-1997008150-A1 | SUBSTITUTED CYCLIC UREAS AND DERIVATIVES THEREOF USEFUL AS RETROVIRAL PROTEASE INHIBITORS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1997-03-06 | — | — | WO | claimed |
| CN-103319470-B | Compound based on the structures of Sant 75 | 北京大学深圳研究生院 | 2017-10-31 | — | — | CN | disclosed |
| EP-1663204-B1 | C-KIT MODULATORS AND METHODS OF USE | EXELIXIS INC (US) | 2014-05-07 | — | — | EP | disclosed |
| US-8362017-B2 | N-[5-chloro-2-(methyloxy)phenyl]-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide; antiproliferative agents; protein kinase inhibitors; drug screening | EXELIXIS, INC. (US) | 2013-01-29 | — | — | US | disclosed |
| US-20080096892-A1 | C-Kit Modulators And Methods Of Use | EXELIXIS, INC. (US) | 2008-04-24 | — | — | US | disclosed |
| US-20080058521-A1 | Processes for the preparation of compounds | WYETH (US) | 2008-03-06 | — | — | US | disclosed |
| US-20070099958-A1 | Protease inhibitors | PROZYMEX A/S (DK) | 2007-05-03 | — | — | US | disclosed |
| EP-1638925-A1 | PROTEASE INHIBITORS | Prozymex A/S (DK) | 2006-03-29 | — | — | EP | disclosed |
| WO-2004110988-A1 | PROTEASE INHIBITORS | PROZYMEX A/S (DK) | 2004-12-23 | — | — | WO | disclosed |
| US-5763469-A | Substituted cyclic ureas and derivatives thereof useful as retroviral protease inhibitors | THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) | 1998-06-09 | — | — | US | disclosed |
| WO-1997008150-A1 | SUBSTITUTED CYCLIC UREAS AND DERIVATIVES THEREOF USEFUL AS RETROVIRAL PROTEASE INHIBITORS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1997-03-06 | — | — | WO | disclosed |
| US-5234946-A | Anticholesterol, antilipemic | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1993-08-10 | — | — | US | disclosed |
| EP-0395768-A1 | SUBSTITUTED ALLYLAMINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1990-11-07 | — | — | EP | disclosed |
| CN-1042910-A | The allylamine derivatives that replaces, their production method and application thereof | BANYU PHARMA CO LTD (JP) | 1990-06-13 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080096892-A1 | C-Kit Modulators And Methods Of Use | KIT, PRKCH, PRKCB | NOTUM 3734/4885PRKCI 52/4885KIF11 2655/4885 |
| US-20070099958-A1 | Protease inhibitors | CTSC, DPP7, BACE1 | NOTUM 368/4885PRKCI 489/4885KIF11 4604/4885 |
| US-20080058521-A1 | Processes for the preparation of compounds | MKI67, MCL1, DCX | NOTUM 1307/4885PRKCI 1225/4885KIF11 2691/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.